Leerink analyst Michael Cherny reiterated a Market Perform rating and $25.00 price target on Hims and Hers (NYSE: HIMS).The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Form 8-K Hims & Hers Health, Inc. For: May 29June 2, 2026 6:09 AM Hims & Hers completes acquisition of EucalyptusJune 2, 2026 5:00 AM HIMS & HERS completes Eucalyptus acquisition to expand in CanadaJune 2, 2026 5:00 AM Hims & Hers completes Eucalyptus acquisition to expand in GermanyJune 2, 2026 5:00 AM Hims & Hers completes Eucalyptus acquisition, enters Australia marketJune 2, 2026 5:00 AM HIMS & Hers completes acquisition of Eucalyptus to enter Japan marketJune 2, 2026 5:00 AM Hims & Hers Completes Acquisition of Eucalyptus, Advancing its Position as the World’s Largest Consumer Health PlatformJune 2, 2026 5:00 AM Hims & Hers Completes Acquisition of Eucalyptus, Accelerating Its Push to Transform Healthcare for CanadiansJune 2, 2026 5:00 AM Hims & Hers Completes Acquisition of Eucalyptus, Advancing Position as the World's Largest Consumer Health PlatformJune 2, 2026 5:00 AM Hims & Hers Completes Acquisition of Eucalyptus, Expanding Access to Comprehensive, Clinically-Backed Weight Management Care in GermanyJune 2, 2026 5:00 AM Hims & Hers Completes Acquisition of Eucalyptus, Parent Company of Juniper, Officially Entering Japanese MarketJune 2, 2026 5:00 AM